HIV-1 Subtype C-Infected Individuals Maintaining High Viral Load as Potential Targets for the “Test-and-Treat” Approach to Reduce HIV Transmission

The first aim of the study is to assess the distribution of HIV-1 RNA levels in subtype C infection. Among 4,348 drug-naïve HIV-positive individuals participating in clinical studies in Botswana, the median baseline plasma HIV-1 RNA levels differed between the general population cohorts (4.1–4.2 log10) and cART-initiating cohorts (5.1–5.3 log10) by about one log10. The proportion of individuals with high (≥50,000 (4.7 log10) copies/ml) HIV-1 RNA levels ranged from 24%–28% in the general HIV-positive population cohorts to 65%–83% in cART-initiating cohorts. The second aim is to estimate the proportion of individuals who maintain high HIV-1 RNA levels for an extended time and the duration of this period. For this analysis, we estimate the proportion of individuals who could be identified by repeated 6- vs. 12-month-interval HIV testing, as well as the potential reduction of HIV transmission time that can be achieved by testing and ARV treating. Longitudinal analysis of 42 seroconverters revealed that 33% (95% CI: 20%–50%) of individuals maintain high HIV-1 RNA levels for at least 180 days post seroconversion (p/s) and the median duration of high viral load period was 350 (269; 428) days p/s. We found that it would be possible to identify all HIV-infected individuals with viral load ≥50,000 (4.7 log10) copies/ml using repeated six-month-interval HIV testing. Assuming individuals with high viral load initiate cART after being identified, the period of high transmissibility due to high viral load can potentially be reduced by 77% (95% CI: 71%–82%). Therefore, if HIV-infected individuals maintaining high levels of plasma HIV-1 RNA for extended period of time contribute disproportionally to HIV transmission, a modified “test-and-treat” strategy targeting such individuals by repeated HIV testing (followed by initiation of cART) might be a useful public health strategy for mitigating the HIV epidemic in some communities.

[1]  Michael J Silverberg,et al.  Effect of early versus deferred antiretroviral therapy for HIV on survival. , 2009, The New England journal of medicine.

[2]  Xiaohua Xia,et al.  Viral dynamics and CD4+ T cell counts in subtype C human immunodeficiency virus type 1-infected individuals from southern Africa. , 2005, AIDS research and human retroviruses.

[3]  Lawrence Corey,et al.  Biological and Virologic Characteristics of Primary HIV Infection , 1998, Annals of Internal Medicine.

[4]  S. Lockman,et al.  Antiretroviral concentrations in breast-feeding infants of women in Botswana receiving antiretroviral treatment. , 2005, The Journal of infectious diseases.

[5]  J. Mellors,et al.  Quantitation of HIV-1 RNA in Plasma Predicts Outcome after Seroconversion , 1995, Annals of Internal Medicine.

[6]  P. Vernazza,et al.  High levels of human immunodeficiency virus type 1 in blood and semen of seropositive men in sub-Saharan Africa. , 1998, The Journal of infectious diseases.

[7]  T. Quinn,et al.  Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. , 2000, The New England journal of medicine.

[8]  Christophe Fraser,et al.  HIV-1 transmission, by stage of infection. , 2008, The Journal of infectious diseases.

[9]  O. Laeyendecker,et al.  Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. , 2005, The Journal of infectious diseases.

[10]  Roger Detels,et al.  Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection , 1997, Annals of Internal Medicine.

[11]  S. Lagakos,et al.  Timing Constraints of In Vivo Gag Mutations during Primary HIV-1 Subtype C Infection , 2009, PloS one.

[12]  D. Kuritzkes,et al.  Higher-Than-Expected Rates of Lactic Acidosis Among Highly Active Antiretroviral Therapy-Treated Women in Botswana: Preliminary Results from a Large Randomized Clinical Trial , 2007, Journal of acquired immune deficiency syndromes.

[13]  I Spijkerman,et al.  AIDS prognosis based on HIV‐1 RNA, CD4+ T‐cell count and function: markers with reciprocal predictive value over time after seroconversion , 1997, AIDS.

[14]  V. Robison,et al.  Male Viral Load and Heterosexual Transmission of HIV‐1 Subtype E in Northern Thailand , 2002, Journal of acquired immune deficiency syndromes.

[15]  S. Lagakos,et al.  Viral Load and CD4+ T-Cell Dynamics in Primary HIV-1 Subtype C Infection , 2009, Journal of acquired immune deficiency syndromes.

[16]  J. Overbaugh,et al.  Correlates of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission: association with maternal plasma HIV-1 RNA load, genital HIV-1 DNA shedding, and breast infections. , 2001, The Journal of infectious diseases.

[17]  James A McIntyre,et al.  Early antiretroviral therapy and mortality among HIV-infected infants. , 2008, The New England journal of medicine.

[18]  J. Goedert,et al.  Virus load and risk of heterosexual transmission of human immunodeficiency virus and hepatitis C virus by men with hemophilia. The Multicenter Hemophilia Cohort Study. , 2000, The Journal of infectious diseases.

[19]  V. DeGruttola,et al.  The reverse transcriptase 67N 70R 215Y genotype is the predominant TAM pathway associated with virologic failure among HIV type 1C-infected adults treated with ZDV/ddI-containing HAART in southern Africa. , 2007, AIDS research and human retroviruses.

[20]  M. Essex,et al.  Identification of primary HIV-1C infection in Botswana , 2008, AIDS care.

[21]  D R Hoover,et al.  Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. , 2001, The New England journal of medicine.

[22]  Sikhulile Moyo,et al.  Evolution of proviral gp120 over the first year of HIV-1 subtype C infection. , 2009, Virology.

[23]  John W. Mellors,et al.  Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma , 1996, Science.

[24]  W. Tsai,et al.  Effects of early, abrupt weaning on HIV-free survival of children in Zambia. , 2008, The New England journal of medicine.

[25]  David Hinkley,et al.  Bootstrap Methods: Another Look at the Jackknife , 2008 .

[26]  S. Lagakos,et al.  Response to antiretroviral therapy after a single, peripartum dose of nevirapine. , 2007, The New England journal of medicine.

[27]  S. Lagakos,et al.  Maternal single-dose nevirapine versus placebo as part of an antiretroviral strategy to prevent mother-to-child HIV transmission in Botswana , 2006, AIDS.

[28]  Lynne Peeples,et al.  Class-sparing regimens for initial treatment of HIV-1 infection. , 2008, The New England journal of medicine.

[29]  W. Blattner,et al.  Rapid clearance of virus after acute HIV-1 infection: correlates of risk of AIDS. , 2004, The Journal of infectious diseases.

[30]  R. Walensky Cost-effectiveness of HIV interventions: from cohort studies and clinical trials to policy. , 2009, Topics in HIV medicine : a publication of the International AIDS Society, USA.

[31]  V. DeGruttola,et al.  Response to Zidovudine/Didanosine-Containing Combination Antiretroviral Therapy Among HIV-1 Subtype C-Infected Adults in Botswana: Two-Year Outcomes from a Randomized Clinical Trial , 2009, Journal of acquired immune deficiency syndromes.

[32]  Douglas D. Richman,et al.  Viral Dynamics of Acute HIV-1 Infection , 1999, The Journal of experimental medicine.

[33]  S. Lockman,et al.  Infant morbidity, mortality, and breast milk immunologic profiles among breast-feeding HIV-infected and HIV-uninfected women in Botswana. , 2007, The Journal of infectious diseases.

[34]  M. Essex,et al.  A seronegative case of HIV-1 subtype C infection in Botswana. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  Christopher Dye,et al.  Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model , 2009, The Lancet.

[36]  D. Ho,et al.  Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. , 1991, The New England journal of medicine.

[37]  M. Moroni,et al.  Plasma Viral Load Concentrations in Women and Men From Different Exposure Categories and With Known Duration of HIV Infection , 2000, Journal of acquired immune deficiency syndromes.

[38]  D. Cooper,et al.  Patterns of viral dynamics during primary human immunodeficiency virus type 1 infection. The Sydney Primary HIV Infection Study Group. , 1998, The Journal of infectious diseases.

[39]  R H Lyles,et al.  Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. , 2000, The Journal of infectious diseases.

[40]  T. Taha,et al.  Natural history and risk factors associated with early and established HIV type 1 infection among reproductive-age women in Malawi. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[41]  J. Margolick,et al.  Sex differences in HIV-1 viral load and progression to AIDS , 1998, The Lancet.

[42]  S. Lagakos,et al.  Better Control of Early Viral Replication Is Associated With Slower Rate of Elicited Antiviral Antibodies in the Detuned Enzyme Immunoassay During Primary HIV-1C Infection , 2009, Journal of acquired immune deficiency syndromes.

[43]  F. Vannberg,et al.  Human Immunodeficiency Virus Type 1 Subtype C Molecular Phylogeny: Consensus Sequence for an AIDS Vaccine Design? , 2002, Journal of Virology.

[44]  S. Vermund,et al.  Impact of small reductions in plasma HIV RNA levels on the risk of heterosexual transmission and disease progression , 2008, AIDS.

[45]  S. Vermund,et al.  Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa. , 2001, AIDS research and human retroviruses.

[46]  M. Fowler,et al.  Predictors of Early and Late Mother-to-Child Transmission of HIV in a Breastfeeding Population: HIV Network for Prevention Trials 012 Experience, Kampala, Uganda , 2009, Journal of acquired immune deficiency syndromes.

[47]  Peter B Gilbert,et al.  Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study. , 2006, JAMA.